Coherus Biosciences (NASDAQ:CHRS) Lifted to C- at TheStreet

TheStreet upgraded shares of Coherus Biosciences (NASDAQ:CHRS) from a d- rating to a c- rating in a report issued on Thursday morning, TheStreetRatingsTable reports.

A number of other equities research analysts have also issued reports on the company. Barclays set a $31.00 target price on Coherus Biosciences and gave the stock a buy rating in a research report on Monday, August 12th. Zacks Investment Research raised Coherus Biosciences from a hold rating to a buy rating and set a $18.00 target price on the stock in a research report on Thursday. ValuEngine lowered Coherus Biosciences from a sell rating to a strong sell rating in a research report on Thursday, October 10th. Maxim Group reaffirmed a buy rating and set a $27.00 target price (up from $25.00) on shares of Coherus Biosciences in a research report on Friday, August 2nd. Finally, BidaskClub lowered Coherus Biosciences from a hold rating to a sell rating in a research report on Wednesday, October 16th. Two research analysts have rated the stock with a sell rating and eight have assigned a buy rating to the stock. The stock currently has a consensus rating of Buy and a consensus target price of $30.38.

Shares of NASDAQ CHRS traded up $0.06 during trading on Thursday, reaching $19.06. The stock had a trading volume of 1,353,200 shares, compared to its average volume of 992,812. The stock has a market cap of $1.14 billion, a PE ratio of -5.92 and a beta of 2.90. The firm’s 50 day moving average price is $19.20 and its two-hundred day moving average price is $19.18. Coherus Biosciences has a one year low of $8.32 and a one year high of $23.91.

Coherus Biosciences (NASDAQ:CHRS) last announced its earnings results on Wednesday, November 6th. The biotechnology company reported $0.63 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.36 by $0.27. The company had revenue of $111.68 million for the quarter, compared to analyst estimates of $93.58 million. On average, sell-side analysts expect that Coherus Biosciences will post 0.89 earnings per share for the current year.

In related news, COO Vincent R. Anicetti sold 2,500 shares of the company’s stock in a transaction on Wednesday, August 14th. The stock was sold at an average price of $19.00, for a total transaction of $47,500.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Jean-Frederic Viret sold 6,318 shares of the company’s stock in a transaction on Wednesday, August 21st. The shares were sold at an average price of $21.71, for a total value of $137,163.78. Following the transaction, the chief financial officer now directly owns 14,831 shares in the company, valued at $321,981.01. The disclosure for this sale can be found here. Insiders have sold 25,264 shares of company stock worth $504,967 over the last ninety days. 18.20% of the stock is owned by insiders.

A number of large investors have recently bought and sold shares of the stock. HighTower Advisors LLC raised its position in Coherus Biosciences by 6.4% during the second quarter. HighTower Advisors LLC now owns 12,184 shares of the biotechnology company’s stock valued at $268,000 after buying an additional 734 shares during the period. Cutler Group LP acquired a new position in Coherus Biosciences during the third quarter valued at $32,000. United Services Automobile Association raised its position in Coherus Biosciences by 0.9% during the second quarter. United Services Automobile Association now owns 217,216 shares of the biotechnology company’s stock valued at $4,800,000 after buying an additional 1,950 shares during the period. Tower Research Capital LLC TRC acquired a new position in Coherus Biosciences during the third quarter valued at $52,000. Finally, Brown Advisory Inc. raised its position in Coherus Biosciences by 0.5% during the second quarter. Brown Advisory Inc. now owns 656,455 shares of the biotechnology company’s stock valued at $14,508,000 after buying an additional 3,061 shares during the period. 96.37% of the stock is currently owned by hedge funds and other institutional investors.

About Coherus Biosciences

Coherus BioSciences, Inc, a commercial-stage biotherapeutics company, focuses on the biosimilar market worldwide. It markets UDENYCA, a long-acting granulocyte-colony stimulating factor, which stimulates production of granulocytes in order to promote the body's ability to fight infections. The company sells UDENYCA in the United States.

Recommended Story: Call Option

Analyst Recommendations for Coherus Biosciences (NASDAQ:CHRS)

Receive News & Ratings for Coherus Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coherus Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.